Comparing histological activity indexes in UC

Gut

Volumn 64, Issue 9, 2015, Pages 1412-1418

  Bressenot, Aude ^a,b   Salleron, Julia ^c   Bastien, Claire ^b   Danese, Silvio ^d   Boulagnon Rombi, Camille ^e   Peyrin Biroulet, Laurent ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c Department of Hepato Gastroenterology University Hospital of Lorraine ^*  (France)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; COLONOSCOPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORRELATIONAL STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; FEMALE; GEBOES INDEX; GLOBAL VISUAL EVALUATION; GRAMLICH INDEX; GUPTA INDEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAMINA PROPRIA; MALE; NEUTROPHIL CHEMOTAXIS; OBSERVER VARIATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; RILEY INDEX; SIGMOIDOSCOPY; ULCERATIVE COLITIS; AGE; COHORT ANALYSIS; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; BIOPSY, NEEDLE; COHORT STUDIES; COLITIS, ULCERATIVE; COLONOSCOPY; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84941266497     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307477     Document Type: Article

References (34)

1. Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55(Suppl 1):i1-15.
2. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
4. Korelitz BI. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis 2010;16:1628-30.
5. Travis SPL, Higgins PDR, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34:113-24.
6. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8.
7. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on long-term outcomes in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012;107:1684-92.
8. Targan SR, Karp LC. Inflammatory bowel disease diagnosis, evaluation and classification: state-of-the art approach. Curr Opin Gastroenterol 2007;23:390-4.
9. Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-83.
10. Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009;15:935-50.
11. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-9.
12. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099-105; quiz 1340-1341.
13. Gramlich T, Petras RE. Pathology of inflammatory bowel disease. Semin Pediatr Surg 2007;16:154-63.
14. Mosli MH, Feagan BG, Sandborn WJ, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014;20:564-75.
15. Danielsson A, Hellers G, Lyrenäs E, et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987;22:987-92.
16. Odze R, Antonioli D, Peppercorn M, et al. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993;17:869-75.
17. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997;50:93-105.
18. Lemmens B, Arijs I, Van Assche G, et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 2013;19:1194-201.
19. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measurement 1960;20:37-46.
20. Krippendorff K. Chapter 11. In: Content analysis, an introduction to its methodology. 2nd edn. Thousand Oaks, CA: Sage Publications, 2004:211-56.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
22. Fleiss J. The design and analysis of clinical experiments. New York, NY: Wiley, 1986:1-31.
23. Langner C, Magro F, Driessen A, et al. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch Int J Pathol 2014;464:409-17.
24. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013;7:827-51.
25. Cooney RM, Warren BF, Altman DG, et al. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17.
26. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
27. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis? Clin Gastroenterol Hepatol 2013;12:929-34.
28. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006;4:203-11.
29. Gibson PR, Fixa B, Pekárková B, et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2006;23:1017-26.
30. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507.
31. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003;1:36-43.
32. Bressenot A, Geboes K, Vignaud J-M, et al. Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease. Inflamm. Bowel Dis 2013;19:1745-52.
33. Jenkins D, Goodall A, Drew K, et al. What is colitis? Statistical approach to distinguishing clinically important inflammatory change in rectal biopsy specimens. J Clin Pathol 1988;41:72-9.
34. Dubucquoi S, Janin A, Klein O, et al. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut 1995;37:242-6.